-46%

est. 2Y upside i

Healthcare

Orchid is a reproductive technology startup that is capable of detecting rare genetic disorders. Orchid’s preconception system analyzes both partners’ genomes and assesses genetic predispositions to common diseases, including heart disease, stroke, schizophrenia, Alzheimer’s disease, breast cancer, and diabetes.

Rank

#3602

Sector

Community Healthcare, Primary Care, Rural Health

Est. Liquidity

~5Y

Data Quality

Data: Low

Orchid Health presents a unique equity opportunity given its status as a profitable Community Benefit Organization with a strong mission in rural healthcare.

Last updated: March 10, 2026

Bull (25%)+75%

Orchid Health successfully scales its 'Wellbeing-First Model' and expands to 10 clinics, exceeding its 2030 patient goal of 20,000. This attracts a strategic acquisition by a larger mission-aligned healthcare system (e.g., a regional non-profit hospital network) at a valuation of ~$45M, representing a strong premium for its proven community impact and operational model.

Base (45%)+10%

Orchid Health continues its steady, profitable growth, expanding to 7-8 clinics and maintaining its strong community ties and patient satisfaction. However, as a Community Benefit Organization, a traditional equity exit is unlikely, and any 'liquidity' would be through a modest acquisition by a smaller regional player or a merger, resulting in a valuation around $28M, offering limited upside for common equity.

Bear (30%)-40%

Increased 'corporatization of care' and potential Medicaid funding cuts severely impact Orchid Health's revenue and ability to compete with larger, well-funded entities. Growth stalls, and the organization faces financial pressure, leading to a distressed acquisition or merger at a significantly reduced valuation of ~$15M, where common equity holders see substantial losses due to preference stack and low valuation.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Based on hypothetical assumptions, if total funding (representing initial capital/debt with preference) is $5M and current valuation is $25.5M, the funding intensity is 19.6%.

Dilution Risk

moderate

As a CBO, future 'funding' is likely to be grants or operational, but any future capital raises or changes in organizational structure could still lead to dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for a private Community Benefit Organization like Orchid Health.

Other — 1 role

View all 1 open roles at Orchid →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Orchid's data — designed to show you've done your homework.

  • 1

    “Given Orchid Health's Community Benefit Organization status, how does the organization define 'equity success' for employees, and what are the realistic pathways for common stock liquidity or value realization?”

  • 2

    “With the ongoing 'corporatization of care' and rural clinic closures, what specific strategies is Orchid Health implementing to defend its market position and ensure long-term independence against larger healthcare incumbents?”

  • 3

    “The 'Wellbeing-First Fellowship' aims to scale your model. How will this initiative directly contribute to the financial sustainability and growth of Orchid Health's clinics, and what are the key metrics for its success beyond impact?”

Community

Valuation Sentiment

Our model estimates -46% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.